Medtronic completes €1.5 billion senior notes public offering

Medtronic plc has just announced the successful closure of a public offering of €1.5 billion of senior notes. The offering included €750 million of 2.950% senior notes due in 2030 and €750 million of 4.200% senior notes due in 2045. These notes were issued by Medtronic, Inc., a wholly-owned subsidiary of Medtronic plc. The Company and Medtronic Global Holdings S.C.A. provided full and unconditional guarantees for these notes on a senior unsecured basis.

The net proceeds from the offering totaled approximately €1.49 billion after deducting underwriting discounts and estimated expenses. These funds are intended to be used to repay existing senior notes due in 2025. Leading financial institutions, such as Deutsche Bank AG, London Branch, and Goldman Sachs & Co. LLC, acted as the joint book-running managers for the offering. Interested parties can access the prospectus related to the offering on the U.S. Securities and Exchange Commission website or obtain copies from the appointed banks.

Medtronic plc, headquartered in Galway, Ireland, is a prominent global healthcare technology company committed to tackling the most pressing health challenges worldwide. With a global workforce of over 95,000 individuals across 150 countries, Medtronic focuses on alleviating pain, restoring health, and extending lives. The company’s innovative technologies and therapies cater to 70 different health conditions, ranging from cardiac devices to patient monitoring systems. Medtronic aims to transform the lives of millions by delivering groundbreaking technologies that make a difference every second, every hour, and every day.

As part of its forward-looking strategy, Medtronic is dedicated to creating exceptional healthcare solutions that go beyond traditional expectations. The company emphasizes individualized care, emphasizes the importance of patient-centric experiences, and strives for superior outcomes. By leveraging its diverse expertise, insatiable curiosity, and commitment to enhancing the lives of others, Medtronic is at the forefront of engineering extraordinary innovations in healthcare.

In compliance with the Private Securities Litigation Reform Act of 1995, Medtronic’s forward-looking statements in this announcement should be considered within the context of cautionary statements and risk factors outlined in various SEC filings, including the most recent Annual Report on Form 10-K. The company does not commit to updating its forward-looking statements based on new information or events.

For further inquiries or details regarding Medtronic plc’s recent public offering and related activities, individuals can contact the Public Relations or Investor Relations departments. Erika Winkels and Ryan Weispfenning can be reached at +1-763-526-8478 and +1-763-505-4626, respectively.